Aadi bioscience announces poster presentations on nab-sirolimus at the international gynecologic cancer society (igcs) 2023 annual global meeting

Aadi initiates  phase 2 trial investigating the combination of nab-sirolimus with letrozole for the treatment of advanced or recurrent endometrioid-type endometrial cancer (eec) los angeles , oct. 19, 2023 /prnewswire/ -- aadi bioscience, inc. (nasdaq: aadi), a biopharmaceutical company focused on developing and commercializing precision therapies for patients with mtor pathway alterations, today announced e-poster presentations at the international gynecologic cancer society (igcs) 2023 annual global meeting, taking place november 5-7, 2023, in seoul, korea. abstract and e-poster presentation details are below: title: "a phase 2, open-label, single-arm, prospective, multi-center study of nab-sirolimus plus letrozole in advanced or recurrent endometrioid endometrial cancer"session title: e-posterdate/time: november 5-7, 2023authors: lauren e.
AADI Ratings Summary
AADI Quant Ranking